Long-term response with sunitinib for metastatic renal cell carcinoma

Urology

Volumn 68, Issue 3, 2006, Pages 672.e19-672.e20

  Ronnen, Ellen A ^a   Kondagunta, G Varuni ^a   Ginsberg, Michelle S ^c   Russo, Paul ^b   Motzer, Robert J ^a  

^a Gastrointestinal Oncology Solid Tumor Service   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIDIARRHEAL AGENT; SUNITINIB;

ADRENAL METASTASIS; AGED; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG DOSE REDUCTION; DRUG RESPONSE; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; STOMATITIS; TUMOR VOLUME;

EID: 33749128978     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.03.042     Document Type: Article

References (8)

1. Motzer R.J., Bander N.H., and Nanus D.M. Renal-cell carcinoma. N Engl J Med 335 (1996) 865-875
2. Fyfe G., Fisher R.I., Rosenberg S.A., et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13 (1995) 688-696
3. Negrier S., Escudier B., Lasset C., et al., Groupe Francais d'Immunotherapie. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 338 (1998) 1272-1278
4. Gunaratnam L., Morley M., Franovic A., et al. Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells. J Biol Chem 278 (2003) 44966-44974
5. Kenck C., Wilhelm M., Bugert P., et al. Mutation of the VHL gene is associated exclusively with the development of non-papillary renal cell carcinomas. J Pathol 179 (1996) 157-161
6. Sosman J.A. Targeting of the VHL-hypoxia-inducible factor-hypoxia-induced gene pathway for renal cell carcinoma therapy. J Am Soc Nephrol 14 (2003) 2695-2702
7. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 16-24
8. Motzer R.J., Rini B.I., Bukowski R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295 (2006) 2516-2524